Alpha 2.0
Login Register
» Articles » PMID: 38421659

GLP-1 Agonists for Obesity-A New Recipe for Success?

Overview
Journal JAMA
Publisher American Medical Association
Specialty General Medicine
Date 2024 Feb 29
PMID 38421659
Authors
Dariush Mozaffarian
Affiliations
Soon will be listed here.
Citing Articles

Dietary Interventions in Heart Failure With Preserved Ejection Fraction: A Scoping Review.

Billingsley H, Carbone S, Driggin E, Kitzman D, Hummel S JACC Adv. 2025; 4(1):101465.

PMID: 39801812 PMC: 11719370. DOI: 10.1016/j.jacadv.2024.101465.

Does Incretin Agonism Have Sustainable Efficacy?.

Janket S, Chatanaka M, Sohaei D, Tamimi F, Meurman J, Diamandis E Cells. 2024; 13(22).

PMID: 39594592 PMC: 11592889. DOI: 10.3390/cells13221842.

Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study.

Shareef L, Khalid S, Raheem M, Al-Hussainy A, Al-Khayyat N, Al Arajy A Cureus. 2024; 16(10):e71569.

PMID: 39553073 PMC: 11564366. DOI: 10.7759/cureus.71569.

Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians.

Despain D, Hoffman B Obes Pillars. 2024; 12:100143.

PMID: 39498283 PMC: 11533596. DOI: 10.1016/j.obpill.2024.100143.

Semaglutide cuts kidney risk in obesity.

Giugliano D, De Nicola L, Maiorino M, Esposito K J Endocrinol Invest. 2024; 48(2):295-298.

PMID: 39495477 DOI: 10.1007/s40618-024-02494-0.